| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 307 | 2024 | 7226 | 20.040 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 87 | 2024 | 995 | 10.610 |
Why?
|
| Sulfonamides | 98 | 2024 | 1921 | 9.580 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 70 | 2024 | 1547 | 6.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 152 | 2024 | 16573 | 5.970 |
Why?
|
| Antineoplastic Agents | 124 | 2024 | 14675 | 5.610 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 71 | 2024 | 2900 | 5.400 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 48 | 2024 | 841 | 4.880 |
Why?
|
| Apoptosis | 125 | 2023 | 7848 | 4.810 |
Why?
|
| Hematologic Neoplasms | 33 | 2024 | 1955 | 3.860 |
Why?
|
| Cytarabine | 56 | 2023 | 2012 | 3.780 |
Why?
|
| Azacitidine | 43 | 2024 | 1215 | 3.750 |
Why?
|
| Leukemia | 30 | 2024 | 1720 | 3.670 |
Why?
|
| Protein Kinase Inhibitors | 71 | 2024 | 4946 | 3.470 |
Why?
|
| Bone Marrow | 37 | 2021 | 2438 | 3.330 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 29 | 2024 | 504 | 3.150 |
Why?
|
| Leukemia, Myeloid | 25 | 2021 | 992 | 3.100 |
Why?
|
| Drug Resistance, Neoplasm | 74 | 2024 | 5404 | 3.090 |
Why?
|
| Philadelphia Chromosome | 36 | 2024 | 834 | 3.080 |
Why?
|
| Oleanolic Acid | 25 | 2012 | 112 | 3.040 |
Why?
|
| Neoplastic Stem Cells | 23 | 2022 | 1469 | 3.010 |
Why?
|
| Myelodysplastic Syndromes | 42 | 2024 | 3146 | 2.900 |
Why?
|
| Receptors, CXCR4 | 17 | 2019 | 279 | 2.840 |
Why?
|
| Humans | 595 | 2024 | 270836 | 2.770 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 34 | 2024 | 2633 | 2.660 |
Why?
|
| Isocitrate Dehydrogenase | 18 | 2023 | 520 | 2.420 |
Why?
|
| Dendritic Cells | 25 | 2024 | 1108 | 2.380 |
Why?
|
| Biphenyl Compounds | 15 | 2021 | 192 | 2.330 |
Why?
|
| Mutation | 97 | 2024 | 15828 | 2.200 |
Why?
|
| Aged | 229 | 2024 | 73010 | 2.040 |
Why?
|
| Prodrugs | 7 | 2021 | 226 | 2.010 |
Why?
|
| Neoplasm Proteins | 20 | 2021 | 3352 | 2.000 |
Why?
|
| Nitrophenols | 14 | 2021 | 95 | 1.990 |
Why?
|
| Tumor Microenvironment | 21 | 2024 | 2978 | 1.960 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 46 | 2024 | 6970 | 1.930 |
Why?
|
| TOR Serine-Threonine Kinases | 16 | 2018 | 1570 | 1.920 |
Why?
|
| Myeloproliferative Disorders | 15 | 2024 | 881 | 1.910 |
Why?
|
| Tumor Suppressor Protein p53 | 34 | 2024 | 3656 | 1.840 |
Why?
|
| Enzyme Inhibitors | 16 | 2024 | 1985 | 1.810 |
Why?
|
| Cell Line, Tumor | 103 | 2024 | 14869 | 1.800 |
Why?
|
| Molecular Targeted Therapy | 16 | 2024 | 2397 | 1.790 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 15 | 2024 | 107 | 1.710 |
Why?
|
| Middle Aged | 227 | 2024 | 89906 | 1.700 |
Why?
|
| Adult | 213 | 2024 | 81477 | 1.690 |
Why?
|
| Fusion Proteins, bcr-abl | 24 | 2023 | 1144 | 1.680 |
Why?
|
| bcl-X Protein | 12 | 2023 | 199 | 1.660 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 13 | 2023 | 319 | 1.650 |
Why?
|
| Aged, 80 and over | 129 | 2024 | 30874 | 1.640 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 20 | 2023 | 288 | 1.640 |
Why?
|
| Remission Induction | 52 | 2023 | 3648 | 1.630 |
Why?
|
| Gene Expression Regulation, Leukemic | 29 | 2020 | 582 | 1.610 |
Why?
|
| Glutaminase | 3 | 2024 | 71 | 1.600 |
Why?
|
| Signal Transduction | 54 | 2024 | 12204 | 1.530 |
Why?
|
| Imidazoles | 31 | 2024 | 1059 | 1.520 |
Why?
|
| Blast Crisis | 18 | 2022 | 587 | 1.440 |
Why?
|
| Animals | 131 | 2024 | 62826 | 1.420 |
Why?
|
| Male | 228 | 2024 | 128405 | 1.390 |
Why?
|
| Recombinant Fusion Proteins | 10 | 2024 | 1667 | 1.370 |
Why?
|
| Mitochondria | 22 | 2022 | 1318 | 1.360 |
Why?
|
| Hypoxia | 4 | 2016 | 467 | 1.350 |
Why?
|
| Piperazines | 35 | 2021 | 2151 | 1.340 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 17 | 2023 | 527 | 1.330 |
Why?
|
| Flow Cytometry | 31 | 2021 | 3079 | 1.330 |
Why?
|
| Pyridazines | 12 | 2024 | 319 | 1.310 |
Why?
|
| Female | 234 | 2024 | 148425 | 1.300 |
Why?
|
| Idarubicin | 17 | 2023 | 459 | 1.300 |
Why?
|
| Phenylurea Compounds | 16 | 2024 | 601 | 1.290 |
Why?
|
| Leukemia, Promyelocytic, Acute | 11 | 2021 | 439 | 1.280 |
Why?
|
| Pyridines | 20 | 2022 | 1310 | 1.240 |
Why?
|
| Young Adult | 100 | 2024 | 22014 | 1.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 20 | 2021 | 2093 | 1.210 |
Why?
|
| Chemokine CXCL12 | 11 | 2019 | 135 | 1.210 |
Why?
|
| Receptors, Cytokine | 9 | 2023 | 183 | 1.200 |
Why?
|
| Mice | 103 | 2024 | 35975 | 1.200 |
Why?
|
| Mice, Inbred NOD | 22 | 2021 | 912 | 1.190 |
Why?
|
| Pyrimidines | 24 | 2021 | 3667 | 1.180 |
Why?
|
| Salvage Therapy | 15 | 2021 | 2117 | 1.170 |
Why?
|
| Hematopoietic Stem Cells | 12 | 2022 | 1372 | 1.140 |
Why?
|
| Nitroimidazoles | 3 | 2016 | 107 | 1.130 |
Why?
|
| Fatty Acids | 4 | 2018 | 448 | 1.120 |
Why?
|
| Oxidative Phosphorylation | 5 | 2023 | 268 | 1.120 |
Why?
|
| Recurrence | 35 | 2024 | 4876 | 1.120 |
Why?
|
| Mice, SCID | 25 | 2021 | 1857 | 1.110 |
Why?
|
| Glutamine | 5 | 2022 | 329 | 1.100 |
Why?
|
| Niacinamide | 13 | 2015 | 428 | 1.070 |
Why?
|
| Acute Disease | 31 | 2023 | 2517 | 1.070 |
Why?
|
| Treatment Outcome | 95 | 2024 | 33796 | 1.070 |
Why?
|
| Proteomics | 6 | 2022 | 1435 | 1.060 |
Why?
|
| Phosphoramide Mustards | 2 | 2016 | 37 | 1.060 |
Why?
|
| Azetidines | 2 | 2024 | 86 | 1.060 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 5 | 2017 | 401 | 1.060 |
Why?
|
| Antibodies, Bispecific | 9 | 2023 | 274 | 1.050 |
Why?
|
| Dancing | 2 | 2022 | 18 | 1.040 |
Why?
|
| PPAR gamma | 7 | 2010 | 231 | 1.030 |
Why?
|
| Cell Proliferation | 42 | 2021 | 7295 | 1.020 |
Why?
|
| U937 Cells | 19 | 2019 | 179 | 1.020 |
Why?
|
| Neoplasm, Residual | 23 | 2023 | 1744 | 1.010 |
Why?
|
| Antigens, CD | 8 | 2023 | 1437 | 1.010 |
Why?
|
| Coculture Techniques | 13 | 2020 | 634 | 1.010 |
Why?
|
| Skin Neoplasms | 14 | 2024 | 4836 | 1.000 |
Why?
|
| Antimetabolites, Antineoplastic | 16 | 2021 | 1343 | 0.990 |
Why?
|
| Xenograft Model Antitumor Assays | 28 | 2024 | 3917 | 0.990 |
Why?
|
| Prognosis | 72 | 2024 | 22421 | 0.980 |
Why?
|
| Piperidines | 7 | 2024 | 1087 | 0.980 |
Why?
|
| Nitrogen Mustard Compounds | 3 | 2015 | 74 | 0.980 |
Why?
|
| Apoptosis Regulatory Proteins | 9 | 2022 | 624 | 0.970 |
Why?
|
| Benzeneacetamides | 3 | 2024 | 42 | 0.960 |
Why?
|
| Tumor Cells, Cultured | 37 | 2021 | 5827 | 0.960 |
Why?
|
| Cell Survival | 30 | 2021 | 3078 | 0.960 |
Why?
|
| Thiadiazoles | 3 | 2024 | 61 | 0.960 |
Why?
|
| Phosphorylation | 40 | 2019 | 4986 | 0.960 |
Why?
|
| Drug Delivery Systems | 6 | 2018 | 662 | 0.950 |
Why?
|
| Stromal Cells | 12 | 2019 | 840 | 0.950 |
Why?
|
| Morpholines | 8 | 2017 | 297 | 0.940 |
Why?
|
| Heterocyclic Compounds | 5 | 2020 | 119 | 0.930 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 10 | 2022 | 475 | 0.920 |
Why?
|
| Vidarabine | 12 | 2022 | 1382 | 0.920 |
Why?
|
| Vincristine | 24 | 2022 | 1575 | 0.900 |
Why?
|
| Cell Differentiation | 21 | 2024 | 4191 | 0.890 |
Why?
|
| Disease-Free Survival | 48 | 2023 | 10253 | 0.880 |
Why?
|
| Cyclophosphamide | 26 | 2022 | 3241 | 0.880 |
Why?
|
| Adipocytes | 5 | 2018 | 308 | 0.880 |
Why?
|
| Thrombocytopenia | 5 | 2021 | 873 | 0.880 |
Why?
|
| Transplantation Conditioning | 7 | 2021 | 2358 | 0.870 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 7 | 2023 | 215 | 0.870 |
Why?
|
| Bone Marrow Cells | 14 | 2021 | 986 | 0.850 |
Why?
|
| Dexamethasone | 24 | 2022 | 1504 | 0.850 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2023 | 1086 | 0.850 |
Why?
|
| Oncogene Proteins, Fusion | 11 | 2020 | 802 | 0.850 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 6 | 2021 | 205 | 0.830 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 7 | 2022 | 775 | 0.810 |
Why?
|
| Neoplasm Recurrence, Local | 21 | 2023 | 10326 | 0.810 |
Why?
|
| HL-60 Cells | 19 | 2021 | 318 | 0.800 |
Why?
|
| Leukemia, Myeloid, Chronic-Phase | 6 | 2020 | 529 | 0.800 |
Why?
|
| Transplantation, Homologous | 13 | 2023 | 3030 | 0.800 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2019 | 272 | 0.790 |
Why?
|
| Proto-Oncogene Proteins | 16 | 2021 | 2617 | 0.790 |
Why?
|
| Benzamides | 19 | 2017 | 1883 | 0.780 |
Why?
|
| Adolescent | 79 | 2024 | 32578 | 0.780 |
Why?
|
| Drug Synergism | 25 | 2019 | 1367 | 0.780 |
Why?
|
| Indazoles | 3 | 2013 | 310 | 0.780 |
Why?
|
| Stem Cell Niche | 3 | 2017 | 94 | 0.770 |
Why?
|
| Leukemia, Experimental | 3 | 2016 | 83 | 0.770 |
Why?
|
| Survival Analysis | 40 | 2021 | 9309 | 0.770 |
Why?
|
| Aniline Compounds | 6 | 2024 | 206 | 0.760 |
Why?
|
| Kaplan-Meier Estimate | 26 | 2021 | 6243 | 0.750 |
Why?
|
| Immune Evasion | 1 | 2021 | 76 | 0.750 |
Why?
|
| Imatinib Mesylate | 15 | 2019 | 1691 | 0.740 |
Why?
|
| Dasatinib | 11 | 2023 | 881 | 0.740 |
Why?
|
| Transcription Factors | 17 | 2023 | 5489 | 0.730 |
Why?
|
| Nuclear Proteins | 15 | 2023 | 3457 | 0.730 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 137 | 0.700 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 8 | 2022 | 388 | 0.700 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 6 | 2022 | 461 | 0.700 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 212 | 0.690 |
Why?
|
| Drug Administration Schedule | 19 | 2021 | 3541 | 0.690 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 12 | 2023 | 2469 | 0.690 |
Why?
|
| Myelitis, Transverse | 1 | 2019 | 13 | 0.680 |
Why?
|
| Intervertebral Disc Degeneration | 1 | 2019 | 22 | 0.670 |
Why?
|
| Doxorubicin | 28 | 2022 | 3139 | 0.670 |
Why?
|
| B-Lymphocytes | 11 | 2023 | 1426 | 0.660 |
Why?
|
| Gene Rearrangement | 9 | 2023 | 813 | 0.660 |
Why?
|
| Retrospective Studies | 68 | 2024 | 39626 | 0.660 |
Why?
|
| MAP Kinase Signaling System | 10 | 2022 | 887 | 0.650 |
Why?
|
| Optic Neuritis | 1 | 2019 | 40 | 0.650 |
Why?
|
| Pyrroles | 4 | 2022 | 592 | 0.650 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2018 | 13 | 0.640 |
Why?
|
| Induction Chemotherapy | 15 | 2023 | 674 | 0.640 |
Why?
|
| Survival Rate | 40 | 2024 | 12488 | 0.630 |
Why?
|
| Blotting, Western | 21 | 2015 | 3650 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 2 | 2015 | 45 | 0.620 |
Why?
|
| Neoplasms | 10 | 2023 | 15835 | 0.610 |
Why?
|
| Receptors, Interleukin-3 | 2 | 2014 | 27 | 0.600 |
Why?
|
| Arabinonucleosides | 8 | 2021 | 458 | 0.600 |
Why?
|
| DNA Modification Methylases | 2 | 2022 | 176 | 0.600 |
Why?
|
| Indoles | 5 | 2019 | 1033 | 0.590 |
Why?
|
| Histone Deacetylase Inhibitors | 6 | 2023 | 627 | 0.580 |
Why?
|
| Cell Cycle | 18 | 2018 | 2150 | 0.580 |
Why?
|
| Tumor Hypoxia | 1 | 2017 | 24 | 0.570 |
Why?
|
| Genomics | 7 | 2022 | 2814 | 0.560 |
Why?
|
| Connective Tissue Growth Factor | 2 | 2013 | 43 | 0.560 |
Why?
|
| Sulfides | 1 | 2016 | 48 | 0.560 |
Why?
|
| Histone Demethylases | 1 | 2018 | 145 | 0.560 |
Why?
|
| Dose-Response Relationship, Drug | 23 | 2019 | 5113 | 0.550 |
Why?
|
| Graft vs Host Disease | 11 | 2024 | 2804 | 0.550 |
Why?
|
| Propensity Score | 7 | 2022 | 771 | 0.540 |
Why?
|
| Cladribine | 7 | 2023 | 253 | 0.540 |
Why?
|
| Benzoxazoles | 1 | 2016 | 40 | 0.540 |
Why?
|
| Energy Metabolism | 5 | 2019 | 1004 | 0.540 |
Why?
|
| Genes, bcl-2 | 5 | 2015 | 176 | 0.540 |
Why?
|
| DNA Methylation | 11 | 2021 | 2736 | 0.530 |
Why?
|
| Amino Acids | 1 | 2019 | 787 | 0.530 |
Why?
|
| Thiazolidines | 1 | 2015 | 15 | 0.530 |
Why?
|
| Busulfan | 3 | 2020 | 787 | 0.530 |
Why?
|
| Aminopyridines | 5 | 2022 | 223 | 0.530 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2015 | 28 | 0.520 |
Why?
|
| Models, Biological | 7 | 2020 | 3225 | 0.520 |
Why?
|
| Stem Cell Transplantation | 9 | 2023 | 1422 | 0.520 |
Why?
|
| Asparaginase | 8 | 2024 | 186 | 0.510 |
Why?
|
| Antineoplastic Agents, Immunological | 8 | 2024 | 1335 | 0.510 |
Why?
|
| Benzimidazoles | 5 | 2021 | 441 | 0.510 |
Why?
|
| Carnitine | 1 | 2015 | 87 | 0.500 |
Why?
|
| Antibodies, Monoclonal, Humanized | 12 | 2021 | 3392 | 0.500 |
Why?
|
| T-Lymphocytes | 15 | 2024 | 3928 | 0.490 |
Why?
|
| Cell Cycle Proteins | 11 | 2023 | 2123 | 0.490 |
Why?
|
| Methyltransferases | 3 | 2022 | 153 | 0.490 |
Why?
|
| Fetal Blood | 4 | 2021 | 503 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 7 | 2022 | 4511 | 0.480 |
Why?
|
| Benzylamines | 5 | 2020 | 101 | 0.480 |
Why?
|
| Histone-Lysine N-Methyltransferase | 5 | 2021 | 462 | 0.480 |
Why?
|
| Peptides, Cyclic | 1 | 2015 | 135 | 0.480 |
Why?
|
| Protein-Tyrosine Kinases | 10 | 2021 | 1836 | 0.470 |
Why?
|
| Pyrazoles | 6 | 2021 | 1541 | 0.470 |
Why?
|
| Follow-Up Studies | 31 | 2021 | 15218 | 0.460 |
Why?
|
| DNA-Binding Proteins | 10 | 2023 | 5039 | 0.460 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2015 | 609 | 0.450 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2020 | 294 | 0.440 |
Why?
|
| Antigens, CD34 | 12 | 2019 | 642 | 0.440 |
Why?
|
| Unrelated Donors | 3 | 2024 | 321 | 0.440 |
Why?
|
| Febrile Neutropenia | 3 | 2024 | 75 | 0.440 |
Why?
|
| Tandem Repeat Sequences | 7 | 2020 | 202 | 0.440 |
Why?
|
| Cell Movement | 7 | 2019 | 2500 | 0.440 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 3 | 2024 | 95 | 0.440 |
Why?
|
| Triazines | 4 | 2022 | 123 | 0.430 |
Why?
|
| para-Aminobenzoates | 3 | 2022 | 11 | 0.430 |
Why?
|
| Benzenesulfonates | 6 | 2012 | 196 | 0.430 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 154 | 0.430 |
Why?
|
| Caspases | 11 | 2011 | 701 | 0.430 |
Why?
|
| Daunorubicin | 5 | 2021 | 313 | 0.420 |
Why?
|
| Primary Myelofibrosis | 4 | 2024 | 902 | 0.420 |
Why?
|
| Purines | 2 | 2023 | 279 | 0.420 |
Why?
|
| Carcinogenesis | 3 | 2021 | 1030 | 0.410 |
Why?
|
| Immunoconjugates | 3 | 2024 | 315 | 0.410 |
Why?
|
| Pyrrolidines | 3 | 2022 | 114 | 0.410 |
Why?
|
| Gossypol | 3 | 2017 | 28 | 0.400 |
Why?
|
| Alleles | 7 | 2020 | 2507 | 0.400 |
Why?
|
| Benzoates | 2 | 2019 | 130 | 0.390 |
Why?
|
| Membrane Microdomains | 1 | 2011 | 83 | 0.380 |
Why?
|
| Sirolimus | 5 | 2022 | 832 | 0.380 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 1379 | 0.380 |
Why?
|
| Lymphoma, Mantle-Cell | 6 | 2017 | 746 | 0.380 |
Why?
|
| Janus Kinase 2 | 5 | 2023 | 753 | 0.370 |
Why?
|
| Cell Communication | 4 | 2009 | 515 | 0.370 |
Why?
|
| Adenine Nucleotides | 5 | 2017 | 366 | 0.370 |
Why?
|
| Histocompatibility Testing | 3 | 2024 | 486 | 0.370 |
Why?
|
| Cell Division | 15 | 2008 | 2715 | 0.370 |
Why?
|
| Mediator Complex Subunit 1 | 1 | 2010 | 9 | 0.370 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 7 | 2017 | 639 | 0.360 |
Why?
|
| RNA, Messenger | 16 | 2016 | 6493 | 0.360 |
Why?
|
| Receptors, Immunologic | 3 | 2023 | 316 | 0.360 |
Why?
|
| Tretinoin | 11 | 2021 | 621 | 0.360 |
Why?
|
| Enzyme Activation | 15 | 2015 | 1837 | 0.360 |
Why?
|
| Lymphoma, B-Cell | 4 | 2023 | 935 | 0.360 |
Why?
|
| Cells, Cultured | 13 | 2021 | 5785 | 0.350 |
Why?
|
| Clonal Evolution | 3 | 2020 | 251 | 0.350 |
Why?
|
| Autophagy | 4 | 2023 | 920 | 0.350 |
Why?
|
| Multiprotein Complexes | 1 | 2012 | 387 | 0.350 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 3 | 2021 | 121 | 0.350 |
Why?
|
| Gene Expression Profiling | 14 | 2021 | 5160 | 0.350 |
Why?
|
| bcl-2-Associated X Protein | 9 | 2022 | 380 | 0.340 |
Why?
|
| src-Family Kinases | 2 | 2014 | 487 | 0.340 |
Why?
|
| NAD+ Nucleosidase | 2 | 2000 | 17 | 0.340 |
Why?
|
| Carrier Proteins | 7 | 2017 | 2126 | 0.340 |
Why?
|
| Biomarkers, Tumor | 16 | 2021 | 10696 | 0.340 |
Why?
|
| Maximum Tolerated Dose | 10 | 2021 | 1323 | 0.340 |
Why?
|
| Chromosome Aberrations | 9 | 2022 | 2023 | 0.340 |
Why?
|
| Triazoles | 4 | 2021 | 632 | 0.340 |
Why?
|
| Methotrexate | 6 | 2022 | 1027 | 0.330 |
Why?
|
| Membrane Proteins | 7 | 2014 | 2953 | 0.330 |
Why?
|
| Transplantation, Haploidentical | 3 | 2019 | 159 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 11 | 2015 | 3655 | 0.330 |
Why?
|
| Gene Expression | 12 | 2016 | 3681 | 0.330 |
Why?
|
| Immunosuppressive Agents | 3 | 2022 | 1456 | 0.320 |
Why?
|
| Nitriles | 6 | 2021 | 943 | 0.320 |
Why?
|
| Disease Management | 4 | 2022 | 1112 | 0.320 |
Why?
|
| Administration, Oral | 7 | 2019 | 1621 | 0.320 |
Why?
|
| Pyrazines | 4 | 2024 | 523 | 0.320 |
Why?
|
| Protein Binding | 8 | 2021 | 3534 | 0.320 |
Why?
|
| Antigens, Differentiation | 2 | 2000 | 254 | 0.310 |
Why?
|
| Proportional Hazards Models | 11 | 2021 | 5080 | 0.310 |
Why?
|
| Lactic Acid | 3 | 2019 | 312 | 0.310 |
Why?
|
| Allografts | 6 | 2022 | 684 | 0.310 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2023 | 1725 | 0.310 |
Why?
|
| Stem Cells | 5 | 2022 | 1229 | 0.310 |
Why?
|
| Membrane Glycoproteins | 8 | 2021 | 1109 | 0.310 |
Why?
|
| Gene Frequency | 4 | 2021 | 1187 | 0.300 |
Why?
|
| Genes, ras | 4 | 2022 | 680 | 0.300 |
Why?
|
| Pneumonia | 3 | 2023 | 787 | 0.300 |
Why?
|
| ras Proteins | 4 | 2022 | 797 | 0.300 |
Why?
|
| Translocation, Genetic | 8 | 2023 | 1287 | 0.300 |
Why?
|
| AMP-Activated Protein Kinases | 4 | 2019 | 405 | 0.300 |
Why?
|
| Benzothiazoles | 3 | 2024 | 101 | 0.300 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 1130 | 0.300 |
Why?
|
| Immunophenotyping | 7 | 2021 | 1728 | 0.300 |
Why?
|
| Consolidation Chemotherapy | 5 | 2020 | 155 | 0.300 |
Why?
|
| Burkitt Lymphoma | 4 | 2023 | 350 | 0.290 |
Why?
|
| Dioxygenases | 3 | 2023 | 170 | 0.290 |
Why?
|
| Cytokines | 5 | 2022 | 2836 | 0.290 |
Why?
|
| Peptide Fragments | 5 | 2017 | 1330 | 0.290 |
Why?
|
| Adenylate Kinase | 2 | 2018 | 36 | 0.290 |
Why?
|
| Disease Susceptibility | 2 | 2020 | 534 | 0.290 |
Why?
|
| NF-kappa B | 6 | 2021 | 1582 | 0.290 |
Why?
|
| Age Factors | 15 | 2024 | 5494 | 0.290 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 4326 | 0.290 |
Why?
|
| Annexin A1 | 1 | 2007 | 41 | 0.290 |
Why?
|
| Activating Transcription Factor 4 | 2 | 2018 | 80 | 0.290 |
Why?
|
| Transplantation, Heterologous | 6 | 2014 | 1088 | 0.280 |
Why?
|
| Cell Line | 12 | 2023 | 5433 | 0.280 |
Why?
|
| Oxidation-Reduction | 5 | 2018 | 718 | 0.280 |
Why?
|
| Cohort Studies | 14 | 2024 | 9425 | 0.280 |
Why?
|
| Glycolysis | 4 | 2021 | 532 | 0.280 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2008 | 229 | 0.280 |
Why?
|
| Cell Hypoxia | 3 | 2012 | 352 | 0.280 |
Why?
|
| Neoplasm Transplantation | 7 | 2019 | 1565 | 0.280 |
Why?
|
| Protein Kinases | 3 | 2008 | 916 | 0.280 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2001 | 44 | 0.280 |
Why?
|
| raf Kinases | 2 | 2007 | 81 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2019 | 2467 | 0.270 |
Why?
|
| Genes, p53 | 5 | 2017 | 1135 | 0.270 |
Why?
|
| Reactive Oxygen Species | 13 | 2021 | 1007 | 0.270 |
Why?
|
| Anemia | 3 | 2020 | 733 | 0.270 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 2 | 2024 | 60 | 0.270 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2020 | 350 | 0.270 |
Why?
|
| Prospective Studies | 20 | 2022 | 13337 | 0.270 |
Why?
|
| Janus Kinases | 4 | 2023 | 175 | 0.270 |
Why?
|
| Clinical Trials as Topic | 8 | 2022 | 3865 | 0.270 |
Why?
|
| Cell Death | 4 | 2018 | 689 | 0.270 |
Why?
|
| Protein Array Analysis | 4 | 2019 | 505 | 0.270 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 3 | 2021 | 275 | 0.270 |
Why?
|
| Disease Models, Animal | 13 | 2024 | 7457 | 0.270 |
Why?
|
| Proteins | 5 | 2021 | 2047 | 0.270 |
Why?
|
| Karyotype | 6 | 2024 | 237 | 0.260 |
Why?
|
| Transcriptome | 10 | 2023 | 1934 | 0.260 |
Why?
|
| Heterografts | 6 | 2020 | 744 | 0.260 |
Why?
|
| Prostaglandin D2 | 2 | 2004 | 26 | 0.260 |
Why?
|
| Interferon-alpha | 4 | 2022 | 960 | 0.260 |
Why?
|
| Antifungal Agents | 4 | 2021 | 876 | 0.260 |
Why?
|
| Biomimetics | 3 | 2017 | 34 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 9078 | 0.250 |
Why?
|
| PAX5 Transcription Factor | 3 | 2022 | 47 | 0.250 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2019 | 162 | 0.250 |
Why?
|
| Quinolines | 2 | 2021 | 402 | 0.250 |
Why?
|
| Single-Cell Analysis | 5 | 2021 | 537 | 0.240 |
Why?
|
| Mycoses | 2 | 2021 | 395 | 0.240 |
Why?
|
| Protein Phosphatase 2 | 4 | 2014 | 90 | 0.240 |
Why?
|
| Retinoid X Receptors | 1 | 2004 | 89 | 0.240 |
Why?
|
| Caveolin 1 | 1 | 2006 | 204 | 0.240 |
Why?
|
| MAP Kinase Kinase Kinases | 2 | 2017 | 188 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2022 | 228 | 0.240 |
Why?
|
| Oxadiazoles | 2 | 2021 | 60 | 0.240 |
Why?
|
| Single-Domain Antibodies | 1 | 2024 | 13 | 0.240 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 5 | 2011 | 76 | 0.240 |
Why?
|
| Enhancer Elements, Genetic | 2 | 2017 | 502 | 0.240 |
Why?
|
| Up-Regulation | 8 | 2023 | 2465 | 0.240 |
Why?
|
| High-Throughput Nucleotide Sequencing | 10 | 2022 | 2332 | 0.230 |
Why?
|
| Repressor Proteins | 5 | 2023 | 1724 | 0.230 |
Why?
|
| Risk Factors | 17 | 2021 | 17818 | 0.230 |
Why?
|
| Uridine | 1 | 2024 | 70 | 0.230 |
Why?
|
| Myeloid Progenitor Cells | 3 | 2021 | 48 | 0.230 |
Why?
|
| Lymphoma | 4 | 2016 | 1514 | 0.230 |
Why?
|
| Chromosome Inversion | 2 | 2023 | 189 | 0.230 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 1733 | 0.230 |
Why?
|
| Patient Safety | 3 | 2018 | 651 | 0.230 |
Why?
|
| Child | 19 | 2024 | 30422 | 0.220 |
Why?
|
| Receptors, Cell Surface | 4 | 2023 | 912 | 0.220 |
Why?
|
| Glycine | 3 | 2021 | 319 | 0.220 |
Why?
|
| Anemia, Refractory | 1 | 2003 | 40 | 0.220 |
Why?
|
| Isoflavones | 1 | 2023 | 76 | 0.220 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 574 | 0.220 |
Why?
|
| Hypoglycemic Agents | 4 | 2012 | 617 | 0.220 |
Why?
|
| Mass Spectrometry | 2 | 2017 | 730 | 0.220 |
Why?
|
| Mercaptopurine | 3 | 2021 | 132 | 0.220 |
Why?
|
| Leukemia, B-Cell | 2 | 2021 | 114 | 0.220 |
Why?
|
| Arsenicals | 2 | 2021 | 203 | 0.220 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2020 | 686 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 5185 | 0.220 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2023 | 191 | 0.210 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2023 | 45 | 0.210 |
Why?
|
| Thalidomide | 3 | 2019 | 600 | 0.210 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 3 | 2016 | 125 | 0.210 |
Why?
|
| Asparagine | 2 | 2019 | 44 | 0.210 |
Why?
|
| Tumor Burden | 5 | 2021 | 2033 | 0.210 |
Why?
|
| Biomarkers | 8 | 2023 | 5105 | 0.210 |
Why?
|
| Mast Cells | 1 | 2024 | 231 | 0.210 |
Why?
|
| STAT3 Transcription Factor | 5 | 2017 | 1146 | 0.210 |
Why?
|
| Nucleosides | 1 | 2022 | 62 | 0.210 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2023 | 100 | 0.210 |
Why?
|
| Gene Silencing | 3 | 2018 | 834 | 0.210 |
Why?
|
| Cellular Microenvironment | 2 | 2012 | 36 | 0.210 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 99 | 0.210 |
Why?
|
| Organic Chemicals | 1 | 2002 | 103 | 0.210 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 1838 | 0.210 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2022 | 28 | 0.210 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2021 | 163 | 0.210 |
Why?
|
| GATA3 Transcription Factor | 2 | 2020 | 144 | 0.210 |
Why?
|
| Leukemia, Monocytic, Acute | 2 | 2017 | 32 | 0.210 |
Why?
|
| Bcl-2-Like Protein 11 | 5 | 2016 | 69 | 0.200 |
Why?
|
| Diphenylamine | 2 | 2012 | 17 | 0.200 |
Why?
|
| THP-1 Cells | 2 | 2019 | 54 | 0.200 |
Why?
|
| Biomimetic Materials | 1 | 2022 | 39 | 0.200 |
Why?
|
| Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2023 | 88 | 0.200 |
Why?
|
| Drug Combinations | 1 | 2024 | 635 | 0.200 |
Why?
|
| Mice, Knockout | 7 | 2021 | 5836 | 0.200 |
Why?
|
| B-Cell Activating Factor | 1 | 2021 | 26 | 0.200 |
Why?
|
| Child, Preschool | 11 | 2024 | 16980 | 0.200 |
Why?
|
| Homeodomain Proteins | 3 | 2015 | 1136 | 0.200 |
Why?
|
| Interferon-gamma | 2 | 2024 | 1184 | 0.200 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 685 | 0.200 |
Why?
|
| Thrombocythemia, Essential | 2 | 2017 | 179 | 0.200 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2021 | 48 | 0.200 |
Why?
|
| Drug Therapy, Combination | 6 | 2021 | 2372 | 0.200 |
Why?
|
| Cysteine | 2 | 2019 | 216 | 0.190 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 484 | 0.190 |
Why?
|
| Receptors, Notch | 2 | 2019 | 377 | 0.190 |
Why?
|
| Cellular Senescence | 1 | 2023 | 390 | 0.190 |
Why?
|
| Ribonucleoproteins | 1 | 2021 | 114 | 0.190 |
Why?
|
| Mice, Transgenic | 8 | 2021 | 4368 | 0.190 |
Why?
|
| Azoles | 1 | 2021 | 48 | 0.190 |
Why?
|
| Cellular Reprogramming Techniques | 1 | 2021 | 28 | 0.190 |
Why?
|
| Mitochondrial Dynamics | 1 | 2021 | 68 | 0.190 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2021 | 61 | 0.190 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2020 | 32 | 0.190 |
Why?
|
| Hematology | 1 | 2022 | 100 | 0.190 |
Why?
|
| Lectins, C-Type | 1 | 2021 | 161 | 0.190 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 3 | 2012 | 135 | 0.180 |
Why?
|
| Jurkat Cells | 3 | 2006 | 318 | 0.180 |
Why?
|
| Membrane Potentials | 5 | 2005 | 464 | 0.180 |
Why?
|
| Polycythemia Vera | 2 | 2017 | 267 | 0.180 |
Why?
|
| Peptides | 1 | 2006 | 1528 | 0.180 |
Why?
|
| Pyruvic Acid | 2 | 2019 | 134 | 0.180 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2020 | 40 | 0.180 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2021 | 176 | 0.180 |
Why?
|
| Histones | 5 | 2019 | 1510 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2020 | 2664 | 0.180 |
Why?
|
| Sarcoma, Myeloid | 1 | 2021 | 94 | 0.180 |
Why?
|
| Drug Evaluation | 1 | 2020 | 436 | 0.180 |
Why?
|
| Caspase 8 | 5 | 2015 | 151 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2021 | 123 | 0.180 |
Why?
|
| MicroRNAs | 5 | 2014 | 2904 | 0.180 |
Why?
|
| Respiratory Insufficiency | 1 | 2024 | 347 | 0.180 |
Why?
|
| Phosphoproteins | 3 | 2015 | 1228 | 0.180 |
Why?
|
| RNA, Small Interfering | 6 | 2017 | 2212 | 0.180 |
Why?
|
| Phenotype | 6 | 2019 | 6454 | 0.180 |
Why?
|
| SEER Program | 1 | 2024 | 1032 | 0.180 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 9036 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 248 | 0.180 |
Why?
|
| Aminoglycosides | 3 | 2016 | 235 | 0.180 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 1212 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2020 | 83 | 0.180 |
Why?
|
| ADP-ribosyl Cyclase 1 | 5 | 2019 | 151 | 0.180 |
Why?
|
| Oxygen | 2 | 2019 | 798 | 0.170 |
Why?
|
| Glucose | 3 | 2017 | 1253 | 0.170 |
Why?
|
| Gene Expression Regulation | 4 | 2021 | 4180 | 0.170 |
Why?
|
| Acetyl Coenzyme A | 1 | 2019 | 23 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2021 | 1136 | 0.170 |
Why?
|
| Protein Isoforms | 4 | 2016 | 860 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 630 | 0.170 |
Why?
|
| Multivariate Analysis | 7 | 2021 | 4332 | 0.170 |
Why?
|
| Autoimmunity | 1 | 2021 | 268 | 0.170 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 641 | 0.170 |
Why?
|
| Killer Cells, Natural | 3 | 2022 | 957 | 0.170 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2021 | 191 | 0.170 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 34 | 0.170 |
Why?
|
| Retreatment | 5 | 2020 | 451 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2021 | 189 | 0.170 |
Why?
|
| Epigenomics | 2 | 2021 | 268 | 0.170 |
Why?
|
| Capillary Leak Syndrome | 1 | 2019 | 12 | 0.170 |
Why?
|
| Aspartate-Ammonia Ligase | 1 | 2019 | 23 | 0.170 |
Why?
|
| Pteridines | 1 | 2019 | 35 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2019 | 66 | 0.170 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2021 | 595 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2014 | 715 | 0.170 |
Why?
|
| Bortezomib | 3 | 2017 | 553 | 0.170 |
Why?
|
| Antigens, CD19 | 4 | 2023 | 584 | 0.170 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2019 | 46 | 0.160 |
Why?
|
| Cell Culture Techniques | 2 | 2019 | 581 | 0.160 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 1055 | 0.160 |
Why?
|
| Point Mutation | 3 | 2019 | 790 | 0.160 |
Why?
|
| Risk | 2 | 2020 | 1915 | 0.160 |
Why?
|
| Immunologic Factors | 3 | 2017 | 671 | 0.160 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2013 | 744 | 0.160 |
Why?
|
| Blood Component Transfusion | 1 | 2019 | 89 | 0.160 |
Why?
|
| Central Nervous System | 1 | 2021 | 459 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2020 | 323 | 0.160 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 202 | 0.160 |
Why?
|
| Receptors, Retinoic Acid | 5 | 2007 | 374 | 0.160 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2019 | 61 | 0.160 |
Why?
|
| Risk Assessment | 6 | 2022 | 6832 | 0.160 |
Why?
|
| Methylation | 2 | 2017 | 625 | 0.160 |
Why?
|
| Multienzyme Complexes | 1 | 2000 | 231 | 0.160 |
Why?
|
| Leukemic Infiltration | 1 | 2018 | 73 | 0.160 |
Why?
|
| Patient Dropouts | 1 | 2019 | 85 | 0.160 |
Why?
|
| Hematopoiesis | 3 | 2009 | 606 | 0.160 |
Why?
|
| Electron Transport | 2 | 2016 | 83 | 0.150 |
Why?
|
| Pilot Projects | 3 | 2020 | 2854 | 0.150 |
Why?
|
| Sepsis | 1 | 2024 | 689 | 0.150 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 1010 | 0.150 |
Why?
|
| Leukemia, Biphenotypic, Acute | 1 | 2018 | 50 | 0.150 |
Why?
|
| Interferon Inducers | 1 | 2017 | 10 | 0.150 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2019 | 100 | 0.150 |
Why?
|
| Acetylation | 4 | 2019 | 518 | 0.150 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2018 | 56 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 28 | 0.150 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2019 | 229 | 0.150 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 120 | 0.150 |
Why?
|
| Ceramides | 2 | 2008 | 97 | 0.150 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 207 | 0.150 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 507 | 0.150 |
Why?
|
| Synthetic Lethal Mutations | 1 | 2017 | 32 | 0.150 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2019 | 221 | 0.150 |
Why?
|
| Multipotent Stem Cells | 1 | 2017 | 54 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2007 | 572 | 0.150 |
Why?
|
| Triterpenes | 3 | 2008 | 68 | 0.150 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2017 | 48 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 5 | 2006 | 687 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 337 | 0.150 |
Why?
|
| DNA Damage | 4 | 2024 | 1974 | 0.150 |
Why?
|
| Chemotaxis | 2 | 2008 | 142 | 0.150 |
Why?
|
| Acrylates | 1 | 2017 | 33 | 0.150 |
Why?
|
| RNA | 1 | 2022 | 1067 | 0.150 |
Why?
|
| Microscopy, Confocal | 3 | 2019 | 671 | 0.150 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2018 | 292 | 0.140 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 1432 | 0.140 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2017 | 512 | 0.140 |
Why?
|
| Base Sequence | 7 | 2016 | 5498 | 0.140 |
Why?
|
| Glutamate Dehydrogenase | 1 | 2016 | 14 | 0.140 |
Why?
|
| Infant | 9 | 2024 | 13923 | 0.140 |
Why?
|
| HLA Antigens | 2 | 2024 | 576 | 0.140 |
Why?
|
| Lymphoma, Follicular | 1 | 2022 | 636 | 0.140 |
Why?
|
| Exotoxins | 1 | 2017 | 76 | 0.140 |
Why?
|
| Down-Regulation | 7 | 2013 | 2108 | 0.140 |
Why?
|
| Hydroxamic Acids | 2 | 2012 | 459 | 0.140 |
Why?
|
| Hydrazines | 1 | 2019 | 214 | 0.140 |
Why?
|
| Leukemia, Prolymphocytic | 2 | 2007 | 54 | 0.140 |
Why?
|
| Trans-Activators | 2 | 2022 | 1651 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2017 | 88 | 0.140 |
Why?
|
| Leukemia, T-Cell | 2 | 2007 | 90 | 0.140 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 397 | 0.140 |
Why?
|
| Glutarates | 1 | 2016 | 42 | 0.140 |
Why?
|
| Biguanides | 1 | 2016 | 10 | 0.140 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 3 | 2017 | 318 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 2 | 2013 | 1773 | 0.140 |
Why?
|
| Pyridones | 4 | 2022 | 361 | 0.140 |
Why?
|
| Luciferases | 3 | 2016 | 462 | 0.140 |
Why?
|
| Single-Chain Antibodies | 1 | 2017 | 60 | 0.140 |
Why?
|
| RNA Interference | 3 | 2019 | 1398 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 182 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 1409 | 0.140 |
Why?
|
| Neutropenia | 3 | 2019 | 1003 | 0.140 |
Why?
|
| Mice, Inbred BALB C | 6 | 2015 | 2473 | 0.140 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2017 | 123 | 0.140 |
Why?
|
| Proteome | 2 | 2017 | 572 | 0.130 |
Why?
|
| Spinal Cord Diseases | 1 | 2017 | 91 | 0.130 |
Why?
|
| Pyrimidinones | 4 | 2022 | 317 | 0.130 |
Why?
|
| Glycerol-3-Phosphate O-Acyltransferase | 1 | 2015 | 3 | 0.130 |
Why?
|
| Tissue Banks | 1 | 2016 | 49 | 0.130 |
Why?
|
| Hyperbilirubinemia | 1 | 2016 | 79 | 0.130 |
Why?
|
| Exanthema | 2 | 2019 | 211 | 0.130 |
Why?
|
| STAT5 Transcription Factor | 1 | 2017 | 227 | 0.130 |
Why?
|
| Protein Kinase C | 2 | 2011 | 420 | 0.130 |
Why?
|
| Arginine | 1 | 2019 | 509 | 0.130 |
Why?
|
| Leukocyte Common Antigens | 2 | 2019 | 192 | 0.130 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 258 | 0.130 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2008 | 309 | 0.130 |
Why?
|
| Depsipeptides | 2 | 2007 | 78 | 0.130 |
Why?
|
| Alternative Splicing | 2 | 2016 | 612 | 0.130 |
Why?
|
| Gene Order | 1 | 2016 | 109 | 0.130 |
Why?
|
| Patient Selection | 2 | 2021 | 2042 | 0.130 |
Why?
|
| Receptors, Erythropoietin | 1 | 2016 | 76 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2015 | 1465 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 435 | 0.130 |
Why?
|
| Bacterial Toxins | 1 | 2017 | 231 | 0.130 |
Why?
|
| Hyperglycemia | 2 | 2012 | 348 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2017 | 291 | 0.130 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2015 | 44 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 1 | 2006 | 2641 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 4 | 2015 | 1214 | 0.130 |
Why?
|
| Naphthoquinones | 1 | 2015 | 19 | 0.130 |
Why?
|
| Lactones | 1 | 2016 | 93 | 0.130 |
Why?
|
| Metabolomics | 1 | 2019 | 505 | 0.130 |
Why?
|
| Cytodiagnosis | 1 | 2016 | 224 | 0.130 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2015 | 28 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 871 | 0.130 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 374 | 0.130 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 337 | 0.130 |
Why?
|
| Caspase 3 | 5 | 2015 | 483 | 0.130 |
Why?
|
| Dimerization | 2 | 2006 | 318 | 0.130 |
Why?
|
| Stomatitis | 1 | 2016 | 193 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 3 | 2009 | 1598 | 0.130 |
Why?
|
| Incidence | 6 | 2024 | 5839 | 0.130 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 11741 | 0.120 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2015 | 40 | 0.120 |
Why?
|
| Carbonic Anhydrases | 1 | 2015 | 52 | 0.120 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 210 | 0.120 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 1 | 2 | 2012 | 47 | 0.120 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 3 | 2011 | 124 | 0.120 |
Why?
|
| Esophagitis | 1 | 2016 | 210 | 0.120 |
Why?
|
| Stem Cell Factor | 1 | 2015 | 88 | 0.120 |
Why?
|
| Immunohistochemistry | 7 | 2019 | 7816 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 442 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2012 | 1292 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2017 | 481 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2015 | 123 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 3 | 2015 | 774 | 0.120 |
Why?
|
| Mice, Nude | 5 | 2017 | 4355 | 0.120 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2021 | 204 | 0.120 |
Why?
|
| Glutamic Acid | 1 | 2016 | 336 | 0.120 |
Why?
|
| Phagocytosis | 2 | 2007 | 296 | 0.120 |
Why?
|
| Enterocolitis | 1 | 2015 | 48 | 0.120 |
Why?
|
| Chromosomes, Human | 1 | 2015 | 278 | 0.120 |
Why?
|
| Intubation, Intratracheal | 1 | 2019 | 454 | 0.120 |
Why?
|
| Immunoblotting | 2 | 2014 | 917 | 0.120 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2014 | 9 | 0.120 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 1 | 2014 | 11 | 0.120 |
Why?
|
| eIF-2 Kinase | 1 | 2015 | 166 | 0.120 |
Why?
|
| Intensive Care Units | 1 | 2019 | 742 | 0.120 |
Why?
|
| DNA | 1 | 2022 | 3071 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2017 | 326 | 0.120 |
Why?
|
| Osteonectin | 1 | 2014 | 56 | 0.120 |
Why?
|
| Integrin alpha4beta1 | 1 | 2014 | 48 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2023 | 2315 | 0.120 |
Why?
|
| Fluorometry | 1 | 2014 | 35 | 0.120 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2008 | 232 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 2 | 2008 | 1502 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 5 | 2020 | 2562 | 0.110 |
Why?
|
| Retinoids | 2 | 2006 | 154 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 1010 | 0.110 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2016 | 184 | 0.110 |
Why?
|
| Chromones | 3 | 2013 | 121 | 0.110 |
Why?
|
| Pruritus | 1 | 2014 | 89 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 843 | 0.110 |
Why?
|
| Necrosis | 1 | 2015 | 605 | 0.110 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 132 | 0.110 |
Why?
|
| Insulin | 4 | 2012 | 1509 | 0.110 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 2351 | 0.110 |
Why?
|
| Time Factors | 10 | 2019 | 13122 | 0.110 |
Why?
|
| Staining and Labeling | 1 | 2015 | 465 | 0.110 |
Why?
|
| Protein Kinase C-alpha | 3 | 2014 | 68 | 0.110 |
Why?
|
| Phenanthrenes | 2 | 2011 | 43 | 0.110 |
Why?
|
| Protein Conformation | 3 | 2021 | 1279 | 0.110 |
Why?
|
| Adenine | 3 | 2021 | 665 | 0.110 |
Why?
|
| Ligands | 4 | 2018 | 1060 | 0.110 |
Why?
|
| Cyclin D1 | 4 | 2012 | 589 | 0.110 |
Why?
|
| Multiple Myeloma | 2 | 2024 | 2322 | 0.110 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 2 | 2020 | 71 | 0.110 |
Why?
|
| Retinoic Acid Receptor alpha | 2 | 2020 | 95 | 0.110 |
Why?
|
| DNA Repair | 2 | 2024 | 1881 | 0.110 |
Why?
|
| Antigens, Neoplasm | 2 | 2021 | 1589 | 0.110 |
Why?
|
| Diterpenes | 2 | 2011 | 117 | 0.110 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 4980 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2015 | 356 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 704 | 0.110 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 671 | 0.100 |
Why?
|
| Thiazolidinediones | 3 | 2012 | 153 | 0.100 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2012 | 69 | 0.100 |
Why?
|
| Glutathione | 3 | 2019 | 377 | 0.100 |
Why?
|
| Transplantation, Heterotopic | 1 | 2012 | 44 | 0.100 |
Why?
|
| Everolimus | 3 | 2017 | 438 | 0.100 |
Why?
|
| Bacteria | 1 | 2017 | 650 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2006 | 1885 | 0.100 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 503 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-raf | 3 | 2012 | 85 | 0.100 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2012 | 44 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 782 | 0.100 |
Why?
|
| fas Receptor | 3 | 2006 | 201 | 0.100 |
Why?
|
| Boronic Acids | 2 | 2010 | 367 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 941 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2020 | 5436 | 0.100 |
Why?
|
| Maintenance Chemotherapy | 3 | 2021 | 221 | 0.100 |
Why?
|
| Breast Neoplasms | 5 | 2013 | 16172 | 0.100 |
Why?
|
| Growth Inhibitors | 3 | 2010 | 164 | 0.100 |
Why?
|
| Hemorrhage | 3 | 2023 | 742 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 1015 | 0.100 |
Why?
|
| Feasibility Studies | 4 | 2022 | 2347 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 203 | 0.100 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 956 | 0.100 |
Why?
|
| Membrane Transport Proteins | 1 | 2012 | 243 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 4 | 2010 | 5219 | 0.100 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 311 | 0.090 |
Why?
|
| Transcriptional Activation | 2 | 2006 | 1145 | 0.090 |
Why?
|
| Coumarins | 1 | 2010 | 37 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2011 | 176 | 0.090 |
Why?
|
| Bacteremia | 1 | 2017 | 720 | 0.090 |
Why?
|
| Nitric Oxide | 3 | 2010 | 664 | 0.090 |
Why?
|
| Adenosine Triphosphate | 3 | 2022 | 599 | 0.090 |
Why?
|
| Transcription, Genetic | 4 | 2007 | 3415 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 4068 | 0.090 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 2 | 2007 | 37 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 2280 | 0.090 |
Why?
|
| Hydroxyurea | 2 | 2022 | 223 | 0.090 |
Why?
|
| Interferon-beta | 1 | 2010 | 109 | 0.090 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 2 | 2009 | 78 | 0.090 |
Why?
|
| Case-Control Studies | 5 | 2020 | 6022 | 0.090 |
Why?
|
| Databases, Factual | 3 | 2024 | 2283 | 0.090 |
Why?
|
| Cell Lineage | 3 | 2021 | 706 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2020 | 1433 | 0.090 |
Why?
|
| Genes, abl | 3 | 2019 | 120 | 0.090 |
Why?
|
| Oligonucleotides | 1 | 2011 | 245 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 7209 | 0.090 |
Why?
|
| ADP-ribosyl Cyclase | 2 | 2000 | 33 | 0.090 |
Why?
|
| Leptin | 4 | 2013 | 313 | 0.090 |
Why?
|
| Cyclins | 3 | 2006 | 469 | 0.090 |
Why?
|
| Diet | 2 | 2024 | 1489 | 0.080 |
Why?
|
| DNA Primers | 3 | 2012 | 1508 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2010 | 192 | 0.080 |
Why?
|
| Fatigue | 3 | 2022 | 1274 | 0.080 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 513 | 0.080 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 4901 | 0.080 |
Why?
|
| United States | 3 | 2024 | 15964 | 0.080 |
Why?
|
| CD3 Complex | 2 | 2023 | 322 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 4 | 2016 | 3243 | 0.080 |
Why?
|
| Myeloid Cells | 2 | 2023 | 272 | 0.080 |
Why?
|
| Mice, Mutant Strains | 2 | 2010 | 665 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2011 | 2288 | 0.080 |
Why?
|
| Proteolysis | 2 | 2021 | 380 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2010 | 242 | 0.080 |
Why?
|
| Mitosis | 2 | 2008 | 690 | 0.080 |
Why?
|
| Metformin | 4 | 2016 | 395 | 0.080 |
Why?
|
| STAT Transcription Factors | 2 | 2023 | 80 | 0.080 |
Why?
|
| Oxides | 2 | 2021 | 211 | 0.080 |
Why?
|
| AraC Transcription Factor | 1 | 2008 | 7 | 0.080 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2006 | 217 | 0.080 |
Why?
|
| Europe | 2 | 2021 | 647 | 0.080 |
Why?
|
| Caspase 9 | 3 | 2010 | 192 | 0.080 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2008 | 91 | 0.080 |
Why?
|
| Aerobiosis | 2 | 2021 | 32 | 0.080 |
Why?
|
| Transfection | 3 | 2014 | 3167 | 0.080 |
Why?
|
| Sarcoma | 1 | 2019 | 1822 | 0.080 |
Why?
|
| Drug Substitution | 2 | 2018 | 86 | 0.080 |
Why?
|
| Disease Progression | 4 | 2021 | 6887 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2005 | 281 | 0.070 |
Why?
|
| Platelet Count | 2 | 2019 | 490 | 0.070 |
Why?
|
| Cell Nucleus | 4 | 2007 | 1742 | 0.070 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2007 | 24 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2015 | 2490 | 0.070 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 485 | 0.070 |
Why?
|
| Mutation, Missense | 3 | 2019 | 1178 | 0.070 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2007 | 38 | 0.070 |
Why?
|
| DNA, Neoplasm | 4 | 2018 | 1960 | 0.070 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2001 | 472 | 0.070 |
Why?
|
| Chromosome Deletion | 2 | 2022 | 1056 | 0.070 |
Why?
|
| Lysine | 2 | 2021 | 427 | 0.070 |
Why?
|
| Transcription Factor HES-1 | 1 | 2007 | 48 | 0.070 |
Why?
|
| Cyclin D | 1 | 2006 | 40 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2005 | 302 | 0.070 |
Why?
|
| Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2006 | 31 | 0.070 |
Why?
|
| Regulatory-Associated Protein of mTOR | 1 | 2006 | 19 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2005 | 298 | 0.070 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2007 | 113 | 0.070 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2006 | 62 | 0.070 |
Why?
|
| Academic Medical Centers | 2 | 2022 | 691 | 0.070 |
Why?
|
| Mice, Inbred CBA | 2 | 2017 | 83 | 0.070 |
Why?
|
| Receptors, Leptin | 3 | 2004 | 68 | 0.070 |
Why?
|
| Granulocytes | 1 | 2007 | 243 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 2083 | 0.070 |
Why?
|
| Melphalan | 2 | 2020 | 878 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2014 | 1084 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 129 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2015 | 2316 | 0.070 |
Why?
|
| Annexin A5 | 2 | 2006 | 75 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2007 | 214 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 34 | 0.070 |
Why?
|
| Comorbidity | 3 | 2022 | 2430 | 0.070 |
Why?
|
| Pregnadienes | 1 | 2005 | 2 | 0.070 |
Why?
|
| Pregnenediones | 1 | 2005 | 4 | 0.070 |
Why?
|
| Genetic Association Studies | 2 | 2020 | 1065 | 0.070 |
Why?
|
| Binding Sites | 3 | 2019 | 2305 | 0.070 |
Why?
|
| Receptors, Leukotriene B4 | 1 | 2005 | 8 | 0.070 |
Why?
|
| Cell Adhesion | 2 | 2014 | 1045 | 0.070 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 290 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 1269 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 130 | 0.060 |
Why?
|
| DNA Fragmentation | 2 | 2005 | 207 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2006 | 102 | 0.060 |
Why?
|
| Receptors, Steroid | 1 | 2007 | 355 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2007 | 957 | 0.060 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2005 | 146 | 0.060 |
Why?
|
| Thiazoles | 2 | 2021 | 729 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2020 | 1472 | 0.060 |
Why?
|
| Flavoproteins | 1 | 2004 | 32 | 0.060 |
Why?
|
| Agar | 1 | 2004 | 28 | 0.060 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2004 | 21 | 0.060 |
Why?
|
| Staurosporine | 3 | 2015 | 150 | 0.060 |
Why?
|
| I-kappa B Kinase | 1 | 2006 | 250 | 0.060 |
Why?
|
| Blood Platelets | 2 | 2019 | 682 | 0.060 |
Why?
|
| Rituximab | 2 | 2021 | 1589 | 0.060 |
Why?
|
| Phosphatidylserines | 1 | 2004 | 73 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 2 | 2003 | 221 | 0.060 |
Why?
|
| Major Histocompatibility Complex | 1 | 2004 | 92 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2008 | 286 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2024 | 41 | 0.060 |
Why?
|
| Histological Techniques | 2 | 2015 | 65 | 0.060 |
Why?
|
| ARNTL Transcription Factors | 1 | 2024 | 52 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 6164 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2021 | 603 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 1655 | 0.060 |
Why?
|
| Sucrose | 1 | 2024 | 67 | 0.060 |
Why?
|
| RNA, Neoplasm | 2 | 2006 | 812 | 0.060 |
Why?
|
| Etoposide | 3 | 2017 | 902 | 0.060 |
Why?
|
| Georgia | 1 | 2023 | 53 | 0.060 |
Why?
|
| Drug Interactions | 2 | 2004 | 586 | 0.060 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2007 | 557 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 460 | 0.060 |
Why?
|
| Cyclin E | 1 | 2005 | 278 | 0.060 |
Why?
|
| Metaphase | 1 | 2003 | 124 | 0.060 |
Why?
|
| Computational Biology | 2 | 2020 | 1264 | 0.060 |
Why?
|
| Cell Growth Processes | 3 | 2010 | 340 | 0.060 |
Why?
|
| Immunotherapy | 3 | 2022 | 3528 | 0.050 |
Why?
|
| Haplotypes | 2 | 2018 | 847 | 0.050 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2023 | 78 | 0.050 |
Why?
|
| G1 Phase | 3 | 2009 | 305 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 2 | 2017 | 675 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 1055 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2007 | 631 | 0.050 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 791 | 0.050 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 634 | 0.050 |
Why?
|
| New York City | 1 | 2022 | 73 | 0.050 |
Why?
|
| Sezary Syndrome | 1 | 2004 | 164 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 263 | 0.050 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 80 | 0.050 |
Why?
|
| K562 Cells | 3 | 2008 | 345 | 0.050 |
Why?
|
| Insulin, Long-Acting | 2 | 2012 | 18 | 0.050 |
Why?
|
| Insulin Glargine | 2 | 2012 | 20 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7929 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2018 | 753 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2023 | 157 | 0.050 |
Why?
|
| CTLA-4 Antigen | 2 | 2018 | 666 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 5306 | 0.050 |
Why?
|
| Income | 1 | 2023 | 228 | 0.050 |
Why?
|
| Plasmids | 1 | 2004 | 952 | 0.050 |
Why?
|
| Oxazoles | 1 | 2022 | 62 | 0.050 |
Why?
|
| Nausea | 2 | 2015 | 540 | 0.050 |
Why?
|
| North America | 1 | 2023 | 340 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2004 | 301 | 0.050 |
Why?
|
| Antiviral Agents | 2 | 2022 | 1254 | 0.050 |
Why?
|
| Pandemics | 2 | 2022 | 1596 | 0.050 |
Why?
|
| beta 2-Microglobulin | 1 | 2002 | 189 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 3076 | 0.050 |
Why?
|
| Electron Transport Complex I | 1 | 2022 | 67 | 0.050 |
Why?
|
| Alanine Transaminase | 1 | 2022 | 240 | 0.050 |
Why?
|
| Estradiol | 1 | 2005 | 885 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2015 | 594 | 0.050 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2023 | 323 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 123 | 0.050 |
Why?
|
| Precision Medicine | 2 | 2022 | 1199 | 0.050 |
Why?
|
| B7 Antigens | 1 | 2022 | 84 | 0.050 |
Why?
|
| Minority Groups | 1 | 2024 | 319 | 0.050 |
Why?
|
| Granzymes | 1 | 2021 | 95 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2016 | 3496 | 0.050 |
Why?
|
| Splicing Factor U2AF | 1 | 2021 | 44 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 4126 | 0.050 |
Why?
|
| Lentivirus | 2 | 2015 | 167 | 0.050 |
Why?
|
| Community Health Services | 1 | 2022 | 129 | 0.050 |
Why?
|
| Gender Identity | 1 | 2021 | 79 | 0.050 |
Why?
|
| Lymphocyte Culture Test, Mixed | 2 | 2014 | 99 | 0.050 |
Why?
|
| Serine-Arginine Splicing Factors | 1 | 2021 | 84 | 0.050 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2021 | 97 | 0.050 |
Why?
|
| Furans | 2 | 2014 | 103 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 450 | 0.050 |
Why?
|
| Calcium | 2 | 2006 | 1645 | 0.050 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2020 | 19 | 0.050 |
Why?
|
| Sex Factors | 2 | 2017 | 2191 | 0.050 |
Why?
|
| Karyotyping | 2 | 2017 | 1065 | 0.050 |
Why?
|
| Mycosis Fungoides | 1 | 2004 | 332 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2022 | 213 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 274 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2021 | 116 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5566 | 0.050 |
Why?
|
| Urate Oxidase | 1 | 2020 | 43 | 0.050 |
Why?
|
| Epoxy Compounds | 2 | 2011 | 57 | 0.050 |
Why?
|
| Receptor, Notch1 | 1 | 2022 | 220 | 0.050 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2020 | 56 | 0.050 |
Why?
|
| Phosphorus | 1 | 2020 | 73 | 0.050 |
Why?
|
| Macrophages | 1 | 2007 | 1369 | 0.050 |
Why?
|
| Antigen Presentation | 1 | 2021 | 289 | 0.050 |
Why?
|
| Leukocytosis | 1 | 2020 | 118 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 125 | 0.040 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2020 | 108 | 0.040 |
Why?
|
| Doxycycline | 1 | 2021 | 178 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 465 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 153 | 0.040 |
Why?
|
| Uric Acid | 1 | 2020 | 128 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 1256 | 0.040 |
Why?
|
| Leukopenia | 1 | 2020 | 153 | 0.040 |
Why?
|
| Gene Knockout Techniques | 1 | 2021 | 272 | 0.040 |
Why?
|
| Graft Survival | 1 | 2004 | 1098 | 0.040 |
Why?
|
| Small Molecule Libraries | 1 | 2021 | 188 | 0.040 |
Why?
|
| Survivorship | 1 | 2020 | 116 | 0.040 |
Why?
|
| Multigene Family | 1 | 2021 | 459 | 0.040 |
Why?
|
| Quality Control | 1 | 2021 | 466 | 0.040 |
Why?
|
| Time | 1 | 2020 | 185 | 0.040 |
Why?
|
| Fluid Therapy | 1 | 2020 | 189 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 1575 | 0.040 |
Why?
|
| Immunotoxins | 1 | 2000 | 120 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 720 | 0.040 |
Why?
|
| Gene Duplication | 2 | 2014 | 433 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 444 | 0.040 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 908 | 0.040 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2015 | 435 | 0.040 |
Why?
|
| Diamines | 1 | 2019 | 25 | 0.040 |
Why?
|
| Thy-1 Antigens | 1 | 2019 | 52 | 0.040 |
Why?
|
| Cell Tracking | 1 | 2019 | 38 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2020 | 347 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 3 | 2008 | 539 | 0.040 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 1999 | 39 | 0.040 |
Why?
|
| Stimulation, Chemical | 1 | 1998 | 114 | 0.040 |
Why?
|
| Histone Deacetylases | 2 | 2015 | 366 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2021 | 577 | 0.040 |
Why?
|
| Dyspnea | 1 | 2022 | 418 | 0.040 |
Why?
|
| Genes, cdc | 1 | 2018 | 84 | 0.040 |
Why?
|
| Isoenzymes | 1 | 2021 | 666 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 249 | 0.040 |
Why?
|
| Diploidy | 1 | 2018 | 116 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1437 | 0.040 |
Why?
|
| Inflammation | 2 | 2023 | 2526 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2007 | 1486 | 0.040 |
Why?
|
| Fas Ligand Protein | 1 | 1999 | 157 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 6416 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2019 | 218 | 0.040 |
Why?
|
| Azepines | 1 | 2019 | 135 | 0.040 |
Why?
|
| Receptors, KIR | 1 | 2018 | 63 | 0.040 |
Why?
|
| Protein Domains | 1 | 2019 | 324 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 423 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 422 | 0.040 |
Why?
|
| Prednisone | 1 | 2021 | 1045 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2019 | 250 | 0.040 |
Why?
|
| Liposomes | 1 | 2000 | 711 | 0.040 |
Why?
|
| Patient Transfer | 1 | 2019 | 138 | 0.040 |
Why?
|
| Nucleotides | 1 | 2018 | 172 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2012 | 286 | 0.040 |
Why?
|
| Chromosomes | 1 | 2019 | 323 | 0.040 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 1008 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 2263 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2017 | 1482 | 0.040 |
Why?
|
| Salmonella typhimurium | 1 | 2017 | 73 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 313 | 0.040 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2018 | 317 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2021 | 351 | 0.040 |
Why?
|
| Genome, Human | 2 | 2017 | 1835 | 0.040 |
Why?
|
| Subacute Combined Degeneration | 1 | 2017 | 16 | 0.040 |
Why?
|
| Naphthyridines | 1 | 2017 | 43 | 0.040 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2010 | 215 | 0.040 |
Why?
|
| Receptor, Cannabinoid, CB2 | 1 | 2017 | 19 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2017 | 1617 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 740 | 0.040 |
Why?
|
| Chromosome Banding | 1 | 2017 | 280 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 465 | 0.040 |
Why?
|
| Ikaros Transcription Factor | 1 | 2017 | 52 | 0.040 |
Why?
|
| MEF2 Transcription Factors | 1 | 2016 | 43 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2017 | 127 | 0.040 |
Why?
|
| Mitoxantrone | 1 | 2017 | 228 | 0.040 |
Why?
|
| Phenformin | 1 | 2016 | 5 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2018 | 405 | 0.040 |
Why?
|
| Colonic Neoplasms | 1 | 2005 | 1434 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 864 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2021 | 1756 | 0.030 |
Why?
|
| Citric Acid Cycle | 1 | 2017 | 94 | 0.030 |
Why?
|
| Rotenone | 1 | 2016 | 38 | 0.030 |
Why?
|
| Autografts | 1 | 2017 | 178 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 614 | 0.030 |
Why?
|
| Cell Count | 1 | 2017 | 524 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2020 | 1080 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2019 | 360 | 0.030 |
Why?
|
| Mitochondrial Proteins | 2 | 2009 | 386 | 0.030 |
Why?
|
| Metabolome | 1 | 2019 | 355 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2017 | 88 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2022 | 806 | 0.030 |
Why?
|
| Injections, Spinal | 1 | 2017 | 276 | 0.030 |
Why?
|
| Protons | 1 | 2019 | 482 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2021 | 879 | 0.030 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2016 | 86 | 0.030 |
Why?
|
| Homocysteine | 1 | 2017 | 150 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2016 | 259 | 0.030 |
Why?
|
| Bone Marrow Examination | 1 | 2016 | 152 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2017 | 125 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2017 | 373 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2017 | 267 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 344 | 0.030 |
Why?
|
| Precursor Cells, T-Lymphoid | 1 | 2016 | 23 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 2016 | 48 | 0.030 |
Why?
|
| Karyopherins | 1 | 2017 | 134 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 82 | 0.030 |
Why?
|
| Cardiolipins | 2 | 2006 | 33 | 0.030 |
Why?
|
| Oncogenes | 1 | 2019 | 700 | 0.030 |
Why?
|
| Telemedicine | 1 | 2022 | 545 | 0.030 |
Why?
|
| Azure Stains | 1 | 2015 | 13 | 0.030 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2017 | 207 | 0.030 |
Why?
|
| Isoquinolines | 1 | 2016 | 126 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2019 | 504 | 0.030 |
Why?
|
| Systems Integration | 1 | 2015 | 79 | 0.030 |
Why?
|
| Protein Transport | 1 | 2018 | 738 | 0.030 |
Why?
|
| Poly I-C | 1 | 2015 | 31 | 0.030 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2015 | 32 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2018 | 505 | 0.030 |
Why?
|
| Tetrahydronaphthalenes | 2 | 2007 | 114 | 0.030 |
Why?
|
| Drug Design | 1 | 2017 | 378 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2015 | 208 | 0.030 |
Why?
|
| Codon | 1 | 2015 | 258 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2016 | 570 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 1063 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 13964 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 245 | 0.030 |
Why?
|
| Age of Onset | 1 | 2017 | 824 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 593 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 1439 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1814 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2020 | 1858 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2016 | 6789 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2020 | 2617 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2015 | 210 | 0.030 |
Why?
|
| Thioguanine | 1 | 2014 | 70 | 0.030 |
Why?
|
| Homeostasis | 1 | 2019 | 961 | 0.030 |
Why?
|
| Propylene Glycols | 1 | 2014 | 39 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2016 | 616 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 747 | 0.030 |
Why?
|
| Sphingosine | 1 | 2014 | 60 | 0.030 |
Why?
|
| CpG Islands | 1 | 2017 | 653 | 0.030 |
Why?
|
| Aldo-Keto Reductase Family 1 Member C3 | 1 | 2014 | 2 | 0.030 |
Why?
|
| Interleukin-3 | 1 | 2014 | 106 | 0.030 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2014 | 50 | 0.030 |
Why?
|
| Folic Acid | 1 | 2017 | 366 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 692 | 0.030 |
Why?
|
| Diphtheria Toxin | 1 | 2014 | 83 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 749 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2017 | 893 | 0.030 |
Why?
|
| Carbazoles | 1 | 2014 | 92 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2014 | 139 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2015 | 315 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 2013 | 51 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 619 | 0.030 |
Why?
|
| YY1 Transcription Factor | 1 | 2013 | 18 | 0.030 |
Why?
|
| Cell Transplantation | 1 | 2013 | 89 | 0.030 |
Why?
|
| Gene Editing | 1 | 2016 | 230 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 1069 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 431 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 673 | 0.030 |
Why?
|
| Flavonoids | 2 | 2007 | 201 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 306 | 0.030 |
Why?
|
| Benzopyrans | 2 | 2004 | 43 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 499 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2019 | 1313 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2014 | 354 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 2202 | 0.030 |
Why?
|
| Sp1 Transcription Factor | 1 | 2014 | 193 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2005 | 718 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 2017 | 627 | 0.030 |
Why?
|
| Stents | 1 | 2019 | 1006 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 644 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2014 | 274 | 0.030 |
Why?
|
| Insulin Aspart | 1 | 2012 | 7 | 0.030 |
Why?
|
| Carcinoma | 1 | 2004 | 2627 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2014 | 581 | 0.030 |
Why?
|
| Medical Records | 1 | 2014 | 443 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2014 | 464 | 0.030 |
Why?
|
| Urea | 1 | 2014 | 306 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 1157 | 0.030 |
Why?
|
| bcl-Associated Death Protein | 2 | 2004 | 24 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 46 | 0.030 |
Why?
|
| Abnormal Karyotype | 1 | 2012 | 101 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 522 | 0.030 |
Why?
|
| C-Peptide | 1 | 2012 | 117 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 60 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 423 | 0.020 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 749 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2011 | 35 | 0.020 |
Why?
|
| Internet | 1 | 2016 | 698 | 0.020 |
Why?
|
| Cell Separation | 1 | 2013 | 616 | 0.020 |
Why?
|
| Replication Protein C | 1 | 2001 | 21 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 491 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2013 | 271 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 211 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 3418 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2015 | 1041 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 704 | 0.020 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 381 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 47 | 0.020 |
Why?
|
| Species Specificity | 1 | 2012 | 811 | 0.020 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2010 | 54 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2010 | 104 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2001 | 116 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2014 | 615 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2049 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 7933 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 264 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2010 | 157 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2014 | 797 | 0.020 |
Why?
|
| Uncoupling Protein 2 | 1 | 2009 | 27 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 1220 | 0.020 |
Why?
|
| Fatty Acid Synthases | 1 | 2009 | 26 | 0.020 |
Why?
|
| beta Catenin | 1 | 2014 | 689 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2012 | 257 | 0.020 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2010 | 109 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2010 | 95 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2013 | 916 | 0.020 |
Why?
|
| Logistic Models | 1 | 2017 | 3435 | 0.020 |
Why?
|
| Bleomycin | 1 | 2001 | 468 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 4643 | 0.020 |
Why?
|
| Models, Animal | 1 | 2012 | 675 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1542 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 175 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2017 | 963 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 5990 | 0.020 |
Why?
|
| Research Design | 1 | 2016 | 1566 | 0.020 |
Why?
|
| Ion Channels | 1 | 2009 | 243 | 0.020 |
Why?
|
| Transgenes | 1 | 2010 | 589 | 0.020 |
Why?
|
| Quality of Life | 1 | 2022 | 4719 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2008 | 193 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 4762 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2014 | 1044 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 619 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 503 | 0.020 |
Why?
|
| Nicotinic Acids | 1 | 2007 | 35 | 0.020 |
Why?
|
| Luciferases, Renilla | 1 | 2007 | 10 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2007 | 95 | 0.020 |
Why?
|
| Fenretinide | 1 | 2007 | 100 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 7780 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2012 | 1288 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 731 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 875 | 0.020 |
Why?
|
| Filgrastim | 1 | 2007 | 195 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2007 | 95 | 0.020 |
Why?
|
| Response Elements | 1 | 2007 | 198 | 0.020 |
Why?
|
| Mitochondria, Liver | 1 | 2007 | 54 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1156 | 0.020 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2007 | 94 | 0.020 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2006 | 18 | 0.020 |
Why?
|
| TNF Receptor-Associated Death Domain Protein | 1 | 2006 | 9 | 0.020 |
Why?
|
| 3-Phosphoinositide-Dependent Protein Kinases | 1 | 2006 | 41 | 0.020 |
Why?
|
| G2 Phase | 1 | 2006 | 218 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2007 | 139 | 0.020 |
Why?
|
| Sphingolipids | 1 | 2006 | 40 | 0.020 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2005 | 26 | 0.020 |
Why?
|
| Isomerism | 1 | 2005 | 67 | 0.020 |
Why?
|
| S Phase | 1 | 2006 | 290 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2010 | 734 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2007 | 296 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2006 | 117 | 0.020 |
Why?
|
| Biotinylation | 1 | 2005 | 47 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2005 | 42 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2006 | 235 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8597 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2005 | 70 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 1158 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2005 | 183 | 0.020 |
Why?
|
| Actins | 1 | 2008 | 615 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2006 | 320 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4389 | 0.020 |
Why?
|
| Calcimycin | 1 | 2004 | 53 | 0.020 |
Why?
|
| Spleen | 1 | 2007 | 735 | 0.020 |
Why?
|
| Ionophores | 1 | 2004 | 25 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 351 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2004 | 117 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 496 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 213 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2007 | 815 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 1312 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2007 | 1036 | 0.010 |
Why?
|
| Progesterone | 1 | 2005 | 730 | 0.010 |
Why?
|
| Antibodies | 1 | 2006 | 837 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 2010 | 1731 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 223 | 0.010 |
Why?
|
| Antioxidants | 1 | 2005 | 520 | 0.010 |
Why?
|
| Retroviridae | 1 | 2003 | 376 | 0.010 |
Why?
|
| Anticarcinogenic Agents | 1 | 2004 | 371 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 2049 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2007 | 2255 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2007 | 1882 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2012 | 1894 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 258 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 1539 | 0.010 |
Why?
|
| Biopsy | 1 | 2008 | 3552 | 0.010 |
Why?
|
| Phosphoserine | 1 | 1999 | 109 | 0.010 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2012 | 2414 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 896 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2004 | 1274 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 720 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 2012 | 3147 | 0.010 |
Why?
|
| Rats | 1 | 2007 | 6659 | 0.010 |
Why?
|
| Testosterone | 1 | 2003 | 732 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 3646 | 0.010 |
Why?
|
| Melanoma | 1 | 2012 | 5522 | 0.010 |
Why?
|